Want to see GB:DXRX full AI Analyst Report?
DXRX Stock Chart & Stats
161.50 p
0.50 p(0.34%)
At close: 4:00 PM EST
161.50 p
0.50 p(0.34%)
Day’s Range― - ―
52-Week Range113.00 p - 180.00 p
Previous CloseN/A
Volume29.93K
Average Volume (3M)79.63K
Market Cap
£123.43M
Enterprise Value114.83M
Total Cash (Recent Filing)£7.34M
Total Debt (Recent Filing)£1.15M
Price to Earnings (P/E)1327.3
Beta0.54
Next Earnings
Sep 29, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding84,922,280
10 Day Avg. Volume58,068
30 Day Avg. Volume79,634
Financial Highlights & Ratios
PEG Ratio-11.04
Price to Book (P/B)2.67
Price to Sales (P/S)2.82
P/FCF Ratio75.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£216.00Price Target Upside33.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)<0.01
Revenue Forecast (FY)£46.32M
Bulls Say, Bears Say
Bulls Say
Contract NegotiationDiaceutics has successfully renegotiated its first PMx contract with the new commercial licensee, which is worth £4.5m in recurring service revenues.
Revenue GrowthAnother year of strong organic revenue growth in FY24 (+36% to £32.2m) and continued momentum into the first four months of 2025 (+35% to £8.4m), puts the business well on track to deliver on current revenue (+25%) and EBITDA expectations for FY25.
Strategic PartnershipsDiaceutics now works with 18 of the top 20 global pharma companies across 56 therapeutic brands, and during FY24 Diaceutics worked with 85 therapies across 52 customers.
Bears Say
Share Price VolatilityAnalyst sees the recent share pullback as a buying opportunity due to the business delivering very strong organic growth and trading on just 2.3x current FY25E EV/sales, despite its superior top-line growth.
Diaceutics News
DXRX FAQ
What was Diaceutics’s price range in the past 12 months?
Diaceutics lowest share price was 113.00 p and its highest was 180.00 p in the past 12 months.
What is Diaceutics’s market cap?
Diaceutics’s market cap is £123.43M.
When is Diaceutics’s upcoming earnings report date?
Diaceutics’s upcoming earnings report date is Sep 29, 2026 which is in 90 days.
How were Diaceutics’s earnings last quarter?
Diaceutics released its earnings results on May 26, 2026. The company reported 0.03 p earnings per share for the quarter, the consensus estimate of 0.03 p by 0 p.
Is Diaceutics overvalued?
According to Wall Street analysts Diaceutics’s price is currently Undervalued.
Does Diaceutics pay dividends?
Diaceutics does not currently pay dividends.
What is Diaceutics’s EPS estimate?
Diaceutics’s EPS estimate is -0.03.
How many shares outstanding does Diaceutics have?
Diaceutics has 84,922,280 shares outstanding.
What happened to Diaceutics’s price movement after its last earnings report?
Diaceutics reported an EPS of 0.03 p in its last earnings report, expectations of 0.03 p. Following the earnings report the stock price went down -9.309%.
Which hedge fund is a major shareholder of Diaceutics?
Currently, no hedge funds are holding shares in GB:DXRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Diaceutics
Diaceutics PLC, established in 2005 and headquartered in Belfast, UK, is a company dedicated to accelerating the commercialization of diagnostic solutions. It offers global pharmaceutical companies comprehensive data, advanced analytics, and implementation support. Central to its operations is the DXRX platform. This platform features DXRX data solutions, providing access to extensive diagnostic testing data pipelines from a broad network of laboratories, including real-time DXRX signal alerts, lab and physician mapping, and a testing dashboard. The DXRX platform also hosts a marketplace where laboratories, pharmaceutical firms, and diagnostic companies can connect to collaborate on precision medicine diagnostics. Diaceutics further provides DXRX Patient Journey, a tool for pharmaceutical clients to conduct detailed longitudinal analyses of individual patient biomarker testing paths, helping identify opportunities for earlier intervention and treatment. DXRX Lab Benchmarking allows laboratories to sharpen their competitive edge by comparing their key criteria against industry counterparts, encompassing metrics such as disease focus, testing methodologies, market share, turnaround times, and their standing as leaders in specific diagnostic fields. The DXRX Test Reimbursement service assists pharma clients in funding novel companion diagnostics, thereby shortening the time required for their widespread adoption. Furthermore, DXRX Test Signal delivers immediate notifications of testing events, empowering pharmaceutical clients to swiftly identify therapeutically actionable patients. Beyond the platform, Diaceutics furnishes services for diagnostic landscape analysis, strategic planning, implementation, and ongoing tracking, alongside expert consulting tailored to precision medicine diagnostics. Its extensive service portfolio also covers test standardization, quality evaluations, optimization of test reports, technical laboratory support, assistance with test access and reimbursement, laboratory training, and various educational resources.
DXRX Company Deck
DXRX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a mix of positive developments, particularly with revenue growth, high gross margins, and the strategic launch of the PMx solution, alongside record order book figures. However, challenges such as the increased EBITDA loss and decreased TCV were noted. The overall sentiment leans towards optimism, driven by strategic advancements and strong financial positioning.View all GB:DXRX earnings summariesDXRX Stock 12 Month Forecast
Average Price Target
216.00 p
▲(33.75% Upside)
Technical Analysis
Options Prices
Currently, No data available
---